keyword
https://read.qxmd.com/read/37607645/high-dose-chemotherapy-and-autologous-stem-cell-transplantation-for-relapsed-or-refractory-primary-mediastinal-large-b-cell-lymphoma
#21
JOURNAL ARTICLE
Hanan Alkhaldi, Alec Reinhardt, Melissa Barnett, Suprateek Kundu, Chitra Hosing, Jeremy Ramdial, Neeraj Saini, Samer Srour, Amin Alousi, Partow Kebriaei, Uday Popat, Muzaffar Qazilbash, Richard Champlin, Elizabeth J Shpall, Allison Gulbis, Terri Lynn Shigle, Bouthaina Dabaja, Chelsea Pinnix, Sairah Ahmed, Raphael Steiner, Borje S Andersson, Yago Nieto
Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon, aggressive type of non-Hodgkin lymphoma. Rituximab-containing chemoimmunotherapy with or without radiation therapy (RT) is standard first-line treatment. Relapsed or refractory (R/R) disease has long been treated with salvage chemotherapy followed by high-dose chemotherapy (HDC), with autologous stem cell transplantation (ASCT) in appropriate patients. We retrospectively analyzed all patients with R/R PMBCL treated with HDC/ASCT at our center between January 2000 and August 2022...
November 2023: Transplantation and cellular therapy
https://read.qxmd.com/read/37603595/outcomes-of-axicabtagene-ciloleucel-in-pmbcl-compare-favorably-to-dlbcl-a-gla-drst-registry-study
#22
JOURNAL ARTICLE
Maria-Luisa Schubert, Wolfgang Andreas Bethge, Francis Ayuketang Ayuk, Malte von Bonin, Vladan Vucinic, Eva Maria Wagner-Drouet, Marion Subklewe, Claudia D Baldus, Bertram Glass, Reinhard Marks, Dimitrios Mougiakakos, Roland Schroers, Matthias Stelljes, Max S Topp, Gerald Georg Wulf, Nicolaus Kröger, Peter Dreger
No abstract text is available yet for this article.
August 21, 2023: Blood Advances
https://read.qxmd.com/read/37560590/central-nervous-system-metastasis-in-a-young-female-patient-with-primary-mediastinal-large-b-cell-lymphoma-a-case-report-and-literature-review
#23
Khalid Talal Alghamdi, Ghaida Abdullah Albattah, Shoug Saleh Alnasyan, Ali Zaki Alhabib, Alaa Mohammed Noor Samkari, Hussam Yousef Kutub
BACKGROUND: Primary mediastinal B-cell lymphoma (PMBCL) is a subtype of diffuse large B-cell lymphoma that originates from a B cell in the thymus. It usually affects young female. CASE DESCRIPTION: A 30-year-old woman presented with mediastinal mass with history of shortness of breath and chest pain. blood analysis showed low levels of hemoglobin, hematocrit, and mean corpuscular volume and high red cell distribution width. A computed tomography (CT)-guided mediastinal core biopsy disclosed primary mediastinal large B-cell lymphoma (PMLBL) with a nongerminal center phenotype and lung tissue infiltrate...
2023: Surgical Neurology International
https://read.qxmd.com/read/37516808/safety-and-efficacy-of-immune-checkpoint-inhibitors-after-allogeneic-hematopoietic-cell-transplantation
#24
REVIEW
Hanan Alkhaldi, Mohamed Kharfan-Dabaja, Riad El Fakih, Mahmoud Aljurf
The immune system plays a major role in preventing infections and cancers. Impairment in immunity may facilitate the development of neoplasia owing to defective immune surveillance, among other mechanisms. Immune evasion plays a significant role in relapse after allogeneic hematopoietic cell transplantation (alloHCT); one purported mechanism is through immune checkpoint signaling pathways. Checkpoint inhibitors (CPIs) are FDA approved for relapsed classical Hodgkin's Lymphoma (cHL), primary mediastinal large B cell Lymphoma (PMBCL) and other solid tumors...
July 29, 2023: Bone Marrow Transplantation
https://read.qxmd.com/read/37440266/pembrolizumab-in-pmbcl-can-it-go-the-distance
#25
EDITORIAL
Lisa Giulino-Roth
No abstract text is available yet for this article.
July 13, 2023: Blood
https://read.qxmd.com/read/37436679/fatal-anterior-mediastinal-mass-in-a-pregnant-lady
#26
JOURNAL ARTICLE
Zhao Peng Koo, Mansharan Kaur Chainchel Singh, Mohamad Helmee Bin Mohamad Noor, Norhayati Binti Omar, Sheue Feng Siew
We report a fatal case of a 26-year-old nulliparous woman who presented with an anterior mediastinal mass in her late pregnancy. She had complained of a progressively increasing neck swelling and occasional dry cough in the early second trimester, which was associated with worsening dyspnoea, reduced effort tolerance and orthopnoea. Ultrasound of the neck showed an enlarged lymph node, and chest X-ray revealed mediastinal widening. At 35 weeks' gestation, the patient was referred to a tertiary centre for a computed tomography (CT) scan of the neck and thorax under elective intubation via awake fibreoptic nasal intubation as she was unable to lie flat...
July 12, 2023: Forensic Science, Medicine, and Pathology
https://read.qxmd.com/read/37427145/radiation-and-dose-densification-of-r-chop-in-primary-mediastinal-b-cell-lymphoma-subgroup-analysis-of-the-unfolder-trial
#27
JOURNAL ARTICLE
Gerhard Held, Lorenz Thurner, Viola Poeschel, German Ott, Christian Schmidt, Konstantinos Christofyllakis, Andreas Viardot, Peter Borchmann, Walburga Engel-Riedel, Norbert Frickhofen, Maike Nickelsen, Ofer Shpilberg, Mathias Witzens-Harig, Frank Griesinger, Beate Krammer-Steiner, Andreas Neubauer, Peter de Nully Brown, Massimo Federico, Bertram Glass, Norbert Schmitz, Gerald Wulf, Lorenz Truemper, Moritz Bewarder, Niels Murawski, Stephan Stilgenbauer, Andreas Rosenwald, Bettina Altmann, Marianne Engelhard, Heinz Schmidberger, Jochen Fleckenstein, Christian Berdel, Markus Loeffler, Marita Ziepert
UNFOLDER (NCT00278408, EUDRACT 2005-005218-19) is a phase-3 trial in patients with aggressive B-cell lymphoma and intermediate prognosis, including primary mediastinal B-cell lymphoma (PMBCL). In a 2 × 2 factorial design, patients were randomized to 6× R-CHOP-14 or R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prediso(lo)ne) and to consolidation radiotherapy to extralymphatic/bulky disease or observation. Response was assessed according to the standardized criteria from 1999, which did not include F-18 fluordesoxyglucose positron emission tomography/computed tomography (FDG-PET) scans...
July 2023: HemaSphere
https://read.qxmd.com/read/37397390/case-report-severe-cutaneous-adverse-event-associated-with-checkpoint-inhibition-in-the-setting-of-car-t-cell-therapy-beyond-crs
#28
Chiara Masucci, Sara Pepe, Ursula La Rocca, Veronica Zullino, Maria Stefania De Propris, Walter Barberi, Anna Paola Iori, Sabina Martelli, Franco Ruberto, Maurizio Martelli, Alice Di Rocco
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy actually represents the standard of care for multiple relapsed or refractory primary mediastinal B-cell lymphoma (r/r PMBCL). Checkpoint inhibitors, such as pembrolizumab, appear to be a safe and effective treatment strategy for patients who are ineligible for or resistant to autologous stem cell transplantation. Although preclinical studies suggested that checkpoint inhibitors may enhance the vitality and anti-tumor activity of CAR T cells, there are no substantial/robust clinical data about the immune-mediated toxicity of their association...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37371815/efficacy-of-immune-checkpoint-blockade-and-biomarkers-of-response-in-lymphoma-a-narrative-review
#29
REVIEW
Sarah Perdikis-Prati, Semira Sheikh, Antonin Bouroumeau, Noémie Lang
Immune checkpoint blockade (ICB) has revolutionized the prognosis of several advanced-stage solid tumors. However, its success has been far more limited in hematological malignancies and is mostly restricted to classical Hodgkin lymphoma (cHL) and primary mediastinal B cell lymphoma (PMBCL). In patients with non-Hodgkin lymphoma (NHL), response to PD-1/PD-L1 ICB monotherapy has been relatively limited, although some subtypes are more sensitive than others. Numerous predictive biomarkers have been investigated in solid malignancies, such as PD-L1 expression, tumor mutational burden (TMB) and microsatellite instability (MSI), among others...
June 15, 2023: Biomedicines
https://read.qxmd.com/read/37297971/efficacy-of-residual-site-radiation-therapy-isrt-in-patients-with-primary-mediastinal-lymphoma-with-deauville-score-4-following-r-cht-results-of-a-retrospective-mono-institutional-study
#30
JOURNAL ARTICLE
Giuseppe Facondo, Mattia Serio, Gianluca Vullo, Maria Paola Bianchi, Sabrina Pelliccia, Alice Di Rocco, Tiziana Lanzolla, Maurizio Valeriani, Arianna Di Napoli, Agostino Tafuri, Maurizio Martelli, Mattia Falchetto Osti, Vitaliana De Sanctis
BACKGROUND: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment (R-ICHT). METHODS: Thirty-one patients with PMBCL were recruited. After completion of R-ICHT, patients were staged with 18F-fluorodeoxyglucose positron-emission tomography, showing DS 4, and were treated with adjuvant RSRT...
May 31, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37289256/efficacy-and-safety-of-geptanolimab-gb226-for-relapsed-refractory-primary-mediastinal-large-b-cell-lymphoma-an-open-label-phase-ii-study-gxplore-003
#31
JOURNAL ARTICLE
Yuankai Shi, Jie Cui, Hui Zhou, Xiaohong Zhang, Liqun Zou, Junning Cao, Yuhuan Gao, Chuan Jin, Xiaoling Li, Hui Liu, Zhigang Peng, Liping Xie, Huilai Zhang, Weihua Zhang, Hongyu Zhang, Liye Zhong, Fang Zhou, Genny Guo, Wenduo He
BACKGROUND: This study aimed to assess the efficacy and safety of geptanolimab (GB226), a fully humanized, recombinant anti-programmed cell death-1 monoclonal antibody, in Chinese patients with refractory or relapsed (r/r) primary mediastinal large B-cell lymphoma (PMBCL). METHODS: This was a multicenter, open-label, single-arm phase II study (Gxplore-003), conducted at 43 hospitals in China (NCT03639181). Patients received geptanolimab intravenously at a dose of 3 mg/kg every 2 weeks until documented confirmed disease progression, intolerable toxicity, or any other cessation criteria was met...
June 8, 2023: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/37260259/treatment-strategies-and-survival-outcomes-of-primary-mediastinal-large-b-cell-lymphoma
#32
JOURNAL ARTICLE
Lin Quan, Zhen He, Xiaoling Zuo, Lei Cao, Yi Wang, Hongyu Dai, Wei Wu, Xiao Shi, Hailing Liu
OBJECTIVES: Primary mediastinal large B-cel l lymphoma (PMBCL) is a rare subtype of B-cell lymphoma that is not yet fully understood. This population-based study aimed to assess the latest survival and treatment strategies for patients with PMBCL. METHODS: The study used the dataset from the Surveillance, Epidemiology, and End Results Program registry to retrospectively analyze adult patients diagnosed with PMBCL between 2001 and 2018. The primary outcome measures included overall survival (OS) and disease-specific survival (DSS)...
December 2023: Hematology (Amsterdam, Netherlands)
https://read.qxmd.com/read/37254478/pediatric-gray-zone-lymphoma-according-to-the-2022-who-classification-an-italian-cohort-study
#33
JOURNAL ARTICLE
Giulia Angela Restivo, Piero Farruggia, Marta Pillon, Maurizio Mascarin, Caterina Elia, Santina Recupero, Paola Muggeo, Celeste Cagnazzo, Daniela Onofrillo, Rosamaria Mura, Ilaria Furfari, Angela Trizzino, Patrizia Bertolini, Alessandra Sala, Raffaela De Santis, Daniela Galimberti, Elisabetta Schiavello, Elisa Carraro
BACKGROUND: The 2022 World Health Organization (WHO) classification redefines the concept of gray zone lymphoma (GZL), restricting it in practice to cases of mediastinal/thymic origin (mediastinal gray zone lymphoma, MGZL) with overlapping features between primary mediastinal B-cell lymphoma (PMBCL) and classical Hodgkin lymphoma (CHL). Cases with histological characteristics of GZL but occurring without mediastinal involvement are better classified as diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS), with few exceptions...
May 30, 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37130017/pembrolizumab-in-relapsed-or-refractory-primary-mediastinal-large-b-cell-lymphoma-final-analysis-of-keynote-170
#34
JOURNAL ARTICLE
Pier Luigi Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Maria Fogliatto, Alejandro Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand
Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (~2 years) in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after or who were ineligible for autologous stem cell transplantation. End points included objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) by investigator per 2007 Response Criteria; overall survival (OS); and safety...
May 2, 2023: Blood
https://read.qxmd.com/read/37074378/primary-mediastinal-thymic-diffuse-large-b-cell-lymphoma-a-population-based-study-on-incidence-and-survival
#35
JOURNAL ARTICLE
Huijie Zhou, Qiuluo Liu, Siyan Lu, Liqun Zou
Primary mediastinal large B-cell lymphoma is a rare subtype of lymphoma. The contemporary incidence of primary mediastinal large B-cell lymphoma remains unknown, and a large population-based study has not been reported. It is essential to provide guidance for further strategies in reducing the disease burden via population-based preventive initiatives. This study aims to explore the epidemiology and effect of therapeutic advances on the survival of patients with primary mediastinal large B-cell lymphoma. This population-based study was conducted using the Surveillance, Epidemiology, and End Results Program (SEER), covering the period from 1975 to 2018...
July 2023: Annals of Hematology
https://read.qxmd.com/read/37046592/characterization-of-mediastinal-bulky-lymphomas-with-fdg-pet-based-radiomics-and-machine-learning-techniques
#36
JOURNAL ARTICLE
Elisabetta Maria Abenavoli, Matteo Barbetti, Flavia Linguanti, Francesco Mungai, Luca Nassi, Benedetta Puccini, Ilaria Romano, Benedetta Sordi, Raffaella Santi, Alessandro Passeri, Roberto Sciagrà, Cinzia Talamonti, Angelina Cistaro, Alessandro Maria Vannucchi, Valentina Berti
BACKGROUND: This study tested the diagnostic value of 18F-FDG PET/CT (FDG-PET) volumetric and texture parameters in the histological differentiation of mediastinal bulky disease due to classical Hodgkin lymphoma (cHL), primary mediastinal B-cell lymphoma (PMBCL) and grey zone lymphoma (GZL), using machine learning techniques. METHODS: We reviewed 80 cHL, 29 PMBCL and 8 GZL adult patients with mediastinal bulky disease and histopathological diagnoses who underwent FDG-PET pre-treatment...
March 23, 2023: Cancers
https://read.qxmd.com/read/36898366/primary-mediastinal-b-cell-lymphoma-in-children-and-young-adults
#37
REVIEW
Christopher J Forlenza, Amy Chadburn, Lisa Giulino-Roth
Primary mediastinal B-cell lymphoma (PMBCL) is a rare but aggressive mature B-cell lymphoma that arises from thymic B cells and most commonly affects adolescents and young adults. PMBCL is now recognized by the WHO as a distinct entity from diffuse large B-cell lymphoma (DLBCL), not otherwise specified, with a unique clinical presentation and distinct morphologic features and molecular alterations. Similar to classic Hodgkin lymphoma, PMBCL tumors are characterized by alterations in the nuclear factor-κB and JAK/STAT pathways...
March 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/36873581/neuropsychiatric-disorders-in-adults-undergoing-chimeric-antigen-receptor-t-cells-therapy-for-aggressive-lymphomas-and-acute-lymphoblastic-leukemia
#38
JOURNAL ARTICLE
Josephine Emole, Odunayo Lawal, Oleksandra Lupak, Hemalatha Rangarajan, Itoro Udo
OBJECTIVE: To evaluate risk factors for neuropsychiatric disorders (NPD) in recipients of CART therapy. METHODS: Patients ≥ 18 years with acute lymphoblastic leukemia (ALL), and aggressive B-cell lymphomas who received CART in 2018 were evaluated. Patients with and without NPD were compared. RESULTS: NPD was diagnosed in 31.2% of patients. Compared to patients without NPD, patients with NPD were likely to be females ( P  = 0...
2023: Leukemia Research Reports
https://read.qxmd.com/read/36798261/characteristics-and-outcomes-of-children-adolescents-and-young-adults-with-relapsed-refractory-non-hodgkin-lymphoma-undergoing-autologous-stem-cell-transplant
#39
Yago Nieto, Oren Pasvolsky, Roland Bassett, Sassine Ghanem, Branko Cuglievan, Priti Tewari, Chitra Hosing, Samer Sr, Jeremy Ramdial, Kris Mahadeo, Sajad Khazal, Demetrios Petropoulos, Uday Popat, Muzaffar Qazilbash, Partow Kebriaei, Richard Champlin, Elizabeth Shpall
There is paucity of data regarding outcomes of children, adolescents and young adults (CAYA) patients with non-Hodgkin lymphoma (NHL) undergoing autologous hematopoietic stem cell transplantation (ASCT). We analyzed 222 patients aged 0-39 years undergoing first ASCT for NHL between 2000 and 2020. The most common histological subtypes were DLBCL (44%), T-NHL (19%) and PMBCL (19%). Younger patients (age ≤ 25) had lower incidence of DLBCL and higher incidence of PMBCL and T-NHL compared to older patients (> 25 years) (P = 0...
February 7, 2023: Research Square
https://read.qxmd.com/read/36773442/a-systematic-review-and-meta-analysis-of-immune-checkpoint-therapy-in-relapsed-or-refractory-non-hodgkin-lymphoma-a-friend-or-foe
#40
REVIEW
Zeinab Davoodi-Moghaddam, Farideh Jafari-Raddani, Maryam Noori, Davood Bashash
Over the last decades, a revolution has occurred in oncology with the development of immune checkpoint inhibitors (ICIs). Following tremendous successes in solid tumors, interest has risen to explore these inhibitors in hematologic malignancies; while Hodgkin's lymphoma (HL) has shown overwhelming achievements, available data on different types of non-Hodgkin's lymphoma (NHL) vary considerably. To the best of our knowledge, no meta-analysis has assessed the efficacy and safety of ICI therapy in relapsed or refractory NHL patients...
February 9, 2023: Translational Oncology
keyword
keyword
100313
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.